Authors
Latest:
Dr Sun on Managing TEAEs of Tisotumab Vedotin in Recurrent/Metastatic HSNCCLova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.
Latest:
Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple MyelomaBorja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse PopulationsCarmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.
Latest:
Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AMLAndrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.
Latest:
Raising the Bar for KRAS G12C+ Colorectal Cancer TreatmentWith 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.
Latest:
Mayo Clinic to Expand Access to State-of-the-Art Cancer Care Through Transformational GiftMayo Clinic will enhance and expand access to cancer care and clinical trials for patients and communities, thanks to a philanthropic commitment.
Latest:
Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin LymphomaMitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.
Latest:
VOD: Ensuring Best OutcomesExperts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.
Latest:
Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL ModelsGaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.
Latest:
Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck CancersA personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.
Latest:
Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCLPeter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.
Latest:
Dr. Woloszynska on the Role of Community Outreach in Addressing Disparities in Prostate CancerAnna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.
Latest:
Dr Cosgrove on the FDA Approval of Mirvetuximab Soravtansine for Frα+ Ovarian CancerCasey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.
Latest:
Dr Mohindra on Updates in SCLC ManagementNisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.
Latest:
Dr Hantel on Eligibility Criteria Associated With Racial/Ethnic Disparities in Clinical Trial Enrollment in AMLAndrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.
Latest:
Megahed on the Effects of NGS on First-Line Treatment Decisions in NSCLCAhmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.
Latest:
Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial CancersMegan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.
Latest:
Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple MyelomaAriel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.
Latest:
Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLLMoritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.
Latest:
Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast CancerNatasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.
Latest:
Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLLLindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.
Latest:
Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid TumorsBob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.
Latest:
Best Practices in Managing Patients on CapivasertibPanelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.
Latest:
Dr. McDermott on Preventing Recurrence of High-Risk Prostate CancerRay McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.
Latest:
Final Thoughts on Case Study and Treating Multiple MyelomaDr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.
Latest:
Normalizing Motherhood in MedicineHematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.
Latest:
Women in Oncology: Self-Advocacy in a Busy FieldMelinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
